A. Floreani

756 total citations
18 papers, 606 citations indexed

About

A. Floreani is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, A. Floreani has authored 18 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 12 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in A. Floreani's work include Liver Disease Diagnosis and Treatment (12 papers), Liver Diseases and Immunity (11 papers) and Liver Disease and Transplantation (7 papers). A. Floreani is often cited by papers focused on Liver Disease Diagnosis and Treatment (12 papers), Liver Diseases and Immunity (11 papers) and Liver Disease and Transplantation (7 papers). A. Floreani collaborates with scholars based in Italy, United States and Switzerland. A. Floreani's co-authors include R. Naccarato, Fabio Farinati, Patrizia Burra, A. Cecchetto, G. Della Libera, R. Cardin, C Marafin, Nicola De Maria, P. Grella and Vincenzo Baldo and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hepatology and Journal of Hepatology.

In The Last Decade

A. Floreani

15 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Floreani Italy 11 371 354 108 81 65 18 606
Jacob Alexander United States 13 237 0.6× 336 0.9× 115 1.1× 69 0.9× 89 1.4× 19 638
H W Hann United States 14 256 0.7× 265 0.7× 68 0.6× 88 1.1× 144 2.2× 22 667
C Marafin Italy 6 267 0.7× 256 0.7× 41 0.4× 76 0.9× 66 1.0× 9 453
Jorge Daruich Argentina 12 479 1.3× 429 1.2× 101 0.9× 28 0.3× 59 0.9× 40 641
Nigel Heaton United Kingdom 14 299 0.8× 229 0.6× 232 2.1× 55 0.7× 52 0.8× 29 559
Theresa Propst Austria 13 228 0.6× 273 0.8× 90 0.8× 61 0.8× 43 0.7× 23 530
Pietro Solero Italy 8 267 0.7× 213 0.6× 56 0.5× 79 1.0× 170 2.6× 9 621
Tullia Maria De Feo Italy 12 234 0.6× 185 0.5× 148 1.4× 39 0.5× 50 0.8× 26 431
Anne McCune United Kingdom 13 226 0.6× 380 1.1× 119 1.1× 39 0.5× 62 1.0× 23 606
Kazuyuki Ohata Japan 9 382 1.0× 538 1.5× 121 1.1× 101 1.2× 16 0.2× 16 766

Countries citing papers authored by A. Floreani

Since Specialization
Citations

This map shows the geographic impact of A. Floreani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Floreani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Floreani more than expected).

Fields of papers citing papers by A. Floreani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Floreani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Floreani. The network helps show where A. Floreani may publish in the future.

Co-authorship network of co-authors of A. Floreani

This figure shows the co-authorship network connecting the top 25 collaborators of A. Floreani. A scholar is included among the top collaborators of A. Floreani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Floreani. A. Floreani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Baldo, Vincenzo, Patrizia Furlan, Claudia Cozzolino, et al.. (2025). Epidemiological trends of cholangiocarcinoma and gallbladder cancer in Northeastern Italy: Administrative analysis over a 17-year period (2007-2023). World Journal of Gastrointestinal Oncology. 17(5). 104229–104229.
2.
Zucchetta, Pietro, et al.. (2022). Surveillance of hepatobiliary cancers in primary sclerosing cholangitis: a preliminary study on the role of PET-MRI. Digestive and Liver Disease. 54. S46–S47.
3.
Bowlus, Christopher L., Michael Trauner, Alberto Liberman, et al.. (2021). Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression. Digestive and Liver Disease. 53. S18–S18.
4.
Floreani, A.. (2020). Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis. SHILAP Revista de lepidopterología. 1 indexed citations
5.
Bowlus, Christopher L., Paul J. Pockros, Andreas E. Kremer, et al.. (2019). Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy. Digestive and Liver Disease. 51. e19–e19. 2 indexed citations
6.
Schiavinato, Alvise, Alberto Zanetto, Giorgia Pantano, et al.. (2017). Polyclonal and monoclonal B lymphocytes response in HCV‐infected patients treated with direct‐acting antiviral agents. Journal of Viral Hepatitis. 24(12). 1168–1176. 18 indexed citations
7.
Franceschet, I., Nora Cazzagon, Alessandra Buja, et al.. (2014). Pregnancy and primary biliary cirrhosis: A case–control study. Digestive and Liver Disease. 46. e57–e57. 3 indexed citations
8.
Taliani, Gloria, Paola Rucci, Elisa Biliotti, et al.. (2007). Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. Journal of Viral Hepatitis. 14(12). 875–882. 13 indexed citations
9.
Floreani, A., Francisco Carmona-Torre, Anna Baragiotta, et al.. (2007). Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clinical & Experimental Immunology. 148(1). 85–89. 19 indexed citations
10.
Floreani, A., Corrado Betterle, I. Carderi, et al.. (2006). Is hepatitis C virus a risk factor for thyroid autoimmunity?. Journal of Viral Hepatitis. 13(4). 272–277. 17 indexed citations
11.
Floreani, A., et al.. (2006). Primary biliary cirrhosis: When and why does the disease develop?. Digestive and Liver Disease. 38(4). 272–275. 7 indexed citations
12.
Onori, Paolo, Domenico Alvaro, A. Floreani, et al.. (2006). Activation of the IGF1 System Characterizes Cholangiocyte Survival During Progression of Primary Biliary Cirrhosis. Journal of Histochemistry & Cytochemistry. 55(4). 327–334. 34 indexed citations
13.
Baldo, Vincenzo, et al.. (2000). Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: A seroepidemiological study. European Journal of Epidemiology. 16(1). 87–91. 34 indexed citations
14.
Floreani, A., et al.. (1999). Hepatic and Extrahepatic Malignancies in Primary Biliary Cirrhosis. Hepatology. 29(5). 1425–1428. 58 indexed citations
15.
Floreani, A., et al.. (1996). S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 67(2). 109–113. 54 indexed citations
16.
Farinati, Fabio, R. Cardin, Nicola De Maria, et al.. (1995). Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. Journal of Hepatology. 22(4). 449–456. 316 indexed citations
17.
Floreani, A., et al.. (1992). Antigliadin antibody classes in chronic liver disease.. PubMed. 24(8). 457–60. 14 indexed citations
18.
Plebani, Mario, et al.. (1990). Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. La Ricerca in Clinica e in Laboratorio. 20(4). 269–274. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob Alexander Breakdown of academic impact, for papers by H W Hann Breakdown of academic impact, for papers by C Marafin Breakdown of academic impact, for papers by Jorge Daruich Breakdown of academic impact, for papers by Nigel Heaton Breakdown of academic impact, for papers by Theresa Propst Breakdown of academic impact, for papers by Pietro Solero Breakdown of academic impact, for papers by Tullia Maria De Feo Breakdown of academic impact, for papers by Anne McCune Breakdown of academic impact, for papers by Kazuyuki Ohata
Rankless by CCL
2026